Novonesis AS (Novonesis AS) Cash And Cash Equivalents

: $163 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

Novonesis AS's quarterly cash and cash equivalents increased from Jun. 2023 ($152.51 Mil) to Sep. 2023 ($168.15 Mil) but then stayed the same from Sep. 2023 ($168.15 Mil) to Dec. 2023 ($163.28 Mil).

Novonesis AS's annual cash and cash equivalents increased from Dec. 2021 ($146.33 Mil) to Dec. 2022 ($148.23 Mil) and increased from Dec. 2022 ($148.23 Mil) to Dec. 2023 ($163.28 Mil).

Novonesis AS Cash And Cash Equivalents Historical Data

The historical data trend for Novonesis AS's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

105.76

193.12

146.33

148.23

163.28

Novonesis AS Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															148.23	158.22	152.51	168.15	163.28

Novonesis AS Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Novonesis AS (OTCPK:NVZMF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Novonesis AS Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Novonesis AS's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis AS (Novonesis AS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis AS (OTCPK:NVZMF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NZYM:Mexico NZYMBc:UK 0Q4U:UK NZYM B:Denmark NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novozymes is the world leader in industrial enzymes. In recent years, the company has expanded into micro-organisms, primarily for agricultural markets. The firm supplies five major industry groups: household care, food and beverages, bioenergy, agriculture and feed, and technical and pharma. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark.

Novonesis AS (Novonesis AS) Headlines

From GuruFocus

2 Holdings to Reduce Based on Analyst Recommendations

By Alberto Abaterusso Alberto Abaterusso • 11-06-2019

Not Just Yogurt Anymore

By PRNewswire • 10-26-2023

Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row

By PRNewswire • 10-03-2023

Novozymes A/S's Dividend Analysis

By GuruFocus Research • 10-19-2023